Avatrombopag maleate

Base Information

• Chemical Name: Avatrombopag maleate
• CAS No.: 677007-74-8
• Molecular Formula: C29H34Cl2N6O3S2.C4H4O4
• UNII: GDW7M2P1IS
• DSSTox Substance ID: DTXSID001027855
• Wikidata: Q27279052
• NCI Thesaurus Code: C142941
• RXCUI: 2045727
• ChEMBL ID: CHEMBL2105758
• Mol file: 677007-74-8.mol

Synonyms:Avatrombopag maleate;E5501 MALEATE;677007-74-8;Avatrombopag maleate [USAN];Avatrombopag (maleate);Avatrombopag Meleate;UNII-GDW7M2P1IS;GDW7M2P1IS;E-5501 MALEATE;(Z)-but-2-enedioic acid;1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid;4-Piperidinecarboxylic acid, 1-(3-chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1- piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-, (2Z)-2-butenedioate (1:1);Doptelet (TN);AKR-501 monomaleate;D0Z5AV;CHEMBL2105758;SCHEMBL19610454;AVATROMBOPAG MALEATE [MI];Avatrombopag maleate (JAN/USAN);AVATROMBOPAG MALEATE [JAN];DTXSID001027855;677007-74-8 (maleate);HY-13463A;AVATROMBOPAG MALEATE [WHO-DD];AVATROMBOPAG MALEATE [ORANGE BOOK];CS-0025423;D10307;A902459;Q27279052;1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2- yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid mono-(2Z)-but-2-enedioate;Avatrombopag

Chemical Property of Avatrombopag maleate

Chemical Property:

• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 9
• Exact Mass: 764.1620453
• Heavy Atom Count: 50
• Complexity: 1050

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl.C(=CC(=O)O)C(=O)O
• Isomeric SMILES: C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl.C(=C\C(=O)O)\C(=O)O
• Recent ClinicalTrials: Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
• Recent EU Clinical Trials: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months